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ABSTRACT
During late mitosis and early G1, replication origins
are licensed for subsequent replication by loading
heterohexamers of the mini-chromosome mainten-
ance proteins (Mcm2-7). To prevent re-replication of
DNA, the licensing system is down-regulated at other
cellcyclestages.Asmallproteincalledgemininplays
an important role in this down-regulation by binding
and inhibiting the Cdt1 component of the licensing
system. We examine here the organization of
Xenopus Cdt1, delimiting regions of Cdt1 required
for licensing and regions required for geminin intera-
ction.TheC-terminal377residuesofCdt1arerequired
for licensing and the extreme C-terminus contains a
domain that interacts with an Mcm(2,4,6,7) complex.
Two regions of Cdt1 interact with geminin: one at the
N-terminus, and one in the centre of the protein. Only
the central region binds geminin tightly enough to
successfully compete with full-length Cdt1 for
gemininbinding.Thisinteractionrequiresapredicted
coiled-coil domain that is conserved amongst metaz-
oan Cdt1 homologues. Geminin forms a homodimer,
with each dimer binding one molecule of Cdt1.
Separation of the domains necessary for licensing
activityfromdomainsrequiredforastronginteraction
with geminin generated a construct, whose licensing
activitywaspartiallyinsensitivetogeminininhibition.
INTRODUCTION
The metazoan genomes are of such considerable size that
thousands of replication origins must be used in order for
them to be replicated in a reasonable length of time. The
use of these replication origins must be strictly regulated to
avoid the over- or under-replication of any given region of the
genome. In order to ensure that each replication origin initiates
DNA replication no more than once per cell cycle, it must ﬁrst
be ‘licensed’ for replication before entering S phase (1,2).
Licensing involves several different proteins, the origin
recognition complex (ORC), Cdc6 and Cdt1 (3), and results
in heterohexamers of Mcm2-7 being loaded onto the DNA.
Mcm2-7 is essential for the initiation and elongation of rep-
lication forks, probably playing a major role in unwinding the
DNA ahead of each replication fork. After entry into S phase,
the activityof the licensingsystem isdown-regulatedto ensure
that no replicated origin can become re-licensed, thus prev-
enting origins ﬁring more than once in each cell cycle.
Cdt1 plays an essential role in the licensing reaction (4–10).
It is recruited to chromatin by ORC (3,4) and directly interacts
with Mcm2-7 (10–12). The activity of Cdt1 is under strict
cell cycle control, being negatively regulated by a small pro-
tein called geminin, which can bind tightly to Cdt1 (7,13–16).
Geminin contains a lengthy section predicted to form a coiled-
coil and which is required to inhibit Cdt1 (13). Re-replication
of chromosomal DNA during S phase and G2 is prevented
largely due to down-regulation of Cdt1 activity (17–21).
In this paper, we make a preliminary investigation of the
structure of Xenopus Cdt1, determining regions required to
provide licensing activity, and regions required for interaction
with geminin. We also demonstrate that geminin forms a
dimer and interacts with Cdt1 in a 2:1 molar ratio. While
this work was in preparation, a paper was published showing
a crystal structure of geminin complexed with a fragment of
Cdt1 (22). Our results provide biochemical corroboration of
some of the conclusions of this crystallographic work.
MATERIALS AND METHODS
Preparation and use of egg extracts
Metaphase-arrested Xenopus egg extracts were prepared as
described previously (23). All extracts were supplemented
with 250 mg/ml cycloheximide, 25 mM phosphocreatine,
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use, and incubations were performed at 23C. Xenopus sperm
nuclei were demembranated with lysolecithin, as described
previously (23), and stored frozen at 80C. For DNA synt-
hesis experiments, sperm nuclei were incubated at a ﬁnal
concentration of 3 ng DNA/ml extract (1000 nuclei/ml),
and extracts (typically 10 ml) were supplemented with
50 mCi/ml [a-
32P]dATP. After a 90 min incubation, DNA
synthesis was assessed by TCA precipitation, as described
previously (23).
Immunodepletion of Cdt1 from extract was performed ess-
entially as described previously (23). Anti-Cdt1 antibody was
coupled to protein A–agarose beads at 2 ml antiserum per ml
beads and washed in EDB-S buffer (50 mM HEPES at pH 7.6,
50 mM KCl, 2 mM DTT, 0.4mM MgCl2, 0.4 mM EGTA, 10%
sucrose, and 10 mg/ml each of leupeptin, pepstatin and aprot-
inin). Metaphase-arrested extract was activated with 0.3 mM
CaCl2 and supplemented with 250 mg/ml cycloheximide, then
mixed with 0.4 vol of antibody beads for 1 h at 4C, after
which the beads were removed. The process was repeated one
more time. Immunoprecipitations were carried out using beads
prepared using the above method.
Plasmids and cloning
Regions of Xenopus Cdt1 were expressed as glutathione
S-transferase (GST) fusions in pGEX-2T (Pharmacia)
encompassing the residues outlined in Figure 1. All constructs
were cloned as BamHI–EcoRI restriction fragments through
the introduction of restriction sites during PCR ampliﬁcation
(primer sequences available on request). Production of His-
tagged Cdt1(193–447) and Cdt1(243–620) was carried out by
recloning the insert from the relevant pGEX-2T clone into the
appropriate pET28 vector.
To produce the Cdt1(193–447) plus mini-geminin complex,
the pET-Duet1 vector (Invitrogen) was used. Cdt1(193–447)
was cloned into MCS1 of pET-Duet1 as a BamHI–EcoRI
fragmenttocontain an N-terminalHistag. Mini-geminin(resi-
dues 87–168) was cloned into MCS2 as a BglII–KpnI restrict-
ion fragment to contain a C-terminal S-tag (primer sequences
available on request).
Recombinant protein production
Expression plasmids were transformed into Escherichia
coli strain BL21(DE3) (Novagen). Cultures were grown in
Figure 1. Summary of constructs used in this paper. The indicated regions of Xenopus Cdt1 were expressed in E.coli as GST fusions. The two regions predicted to
form coiled-coils are indicated with cross hatching. Where deletions are predicted to significantly disrupt coiled-coil formation, the cross-hatching is replaced by
diagonalshading.Resultsfortheassaysoutlinedinsubsequentfiguresaresummarizedontheright.Datanotexplicitlyshowninthispaperareindicatedbyasterisk.
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0.6–0.7 before the addition of 1 mM isopropyl-b-D-
thiogalactopyranoside and grown for a further 3 h. The
cells were lysed using Bugbuster (Novagen) according to
the manufacturer’s instructions.
GST-Cdt1(193–243) and GST-Cdt1(447–479) were soluble
and were bound to glutathione Sepharose 4B (Pharmacia)
according to the manufacturer’s instructions and eluted with
50 mM Tris–HCl, pH 8, plus 10 mM glutathione. All other
GST fusion proteins were present in inclusion bodies and were
solubilized using a detergent cancellation technique (24,25).
The resulting protein preparation was then bound to glutathi-
one Sepharose 4B as described above but with an additional
second series of elution steps using 50 mM Tris–HCl, pH 8,
200 mM KCl, 8 M Urea, 10 mM glutathione and 0.03% Triton.
Eluted protein was dialysed in Tube-O-Dialyser tubes (Geno-
Tech) against 100· vol of THED 200 (0.03% Triton, 20 mM
HEPES, pH 8, 20% ethylene glycol, 1 mM DTT and 200 mM
KCl) containing progressively lower concentrations of urea,
4 M, overnight, then 2 h at 2 M, 1 M and two steps without
urea. All constructs described in this paper are GST-tagged,
except where explicitly stated.
His-tagged geminin
DEL (13) and the complex of His-
Cdt1(193–447) and S-tagged mini-geminin (residues 87–
168) were puriﬁed using Ni-NTA agarose beads (Qiagen)
added directly to the protein suspension produced following
Bugbuster treatment (supplemented with 10 mM imidazole).
Beadswere washedthoroughlywithphosphate-bufferedsaline
(PBS)containing 20mMimidazoleand300mMKCl.Proteins
were eluted using the same buffer but containing 250 mM
imidazole.
When expressed in the absence of geminin, recombinantly
expressed His-Cdt1(1–620), His-Cdt1(193–447) and His-
Cdt1(243–620) were present in inclusion bodies and were
solubilized using IMAC5 (20 mM Tris, pH 8, 0.5 M NaCl,
5 mM imidazole and 8 M urea). Ni-NTA agarose beads were
added to the solubilized inclusion bodies and a puriﬁcation
similar to that for soluble His-tagged proteins was followed,
with 8 M urea present in all buffers. Elutions containing the
highest concentration of protein were dialysed into THED 200
in the same manner as the insoluble GST fusion proteins.
To quantify protein concentration, samples were run on
SDS–PAGE and stained with Coomassie; gels were scanned
on a ﬂatbed scanner and the images quantiﬁed using AIDA
software version 3.27.001 (Fuji).
Chromatin isolation
For immunoblotting experiments, 20 ml aliquots of Cdt1-
depleted extract were combined with dilutions of GST-Cdt1
constructs and supplemented with demembranated sperm
nuclei at a ﬁnal concentration of 10 ng DNA/ml extract
(3000 nuclei/ml). After a 30 min incubation, each reaction
was diluted in 500 ml NIBA (50 mM KCl, 50 mM HEPES
KOH, pH 7.6, 5 mM MgCl2, 2 mM DTT, 0.5 mM spermidine,
0.15 mM spermine, 2.5 mM Mg-ATP, and 1 mg/ml each of
leupeptin, pepstatin and aprotinin) supplemented with 0.1%
Triton X-100 and under-layered with 100 ml of the same buffer
containing 15% sucrose. The chromatin was pelleted at 2100 g
in a swinging bucket centrifuge for 5 min at 4C. The diluted
extract and the majority of the overlying cushion were then
removed, and the chromatin was re-centrifuged at 13000 g for
2 min in a ﬁxed-angle rotor. The chromatin pellet was resusp-
ended in loading buffer and subjected to immunoblotting by
standard techniques using 4–12% Bis-Tris gradient SDS–
PAGE (Invitrogen) and enhanced chemiluminescence (ECL)
detection (SuperSignal1 West Pico Chemiluminescent).
Two-step licensing assay
A two-step licensing assay speciﬁc for Cdt1 activity was used
based on a previously described two-step assay (23,26). Sperm
nuclei were ﬁrst incubated in a small volume of Cdt1-depleted
extract (which provides nucleoplasmin, ORC, Cdc6 and
Mcm2-7 activities) supplemented with various Cdt1 cons-
tructs. The ability of the DNA to subsequently replicate in
whole extract supplemented with active recombinant geminin
reﬂects its degree of licensing. This is formally equivalent to
the previously validated 6-DMAP assay (23,26) since we have
recently shown that the only replication defect in 6-DMAP-
treated extracts is the presence of active geminin (27). Ali-
quots containing 1 ml samples of GST-Cdt1 constructs were
combined with 1.1 ml of Cdt1-depleted extract containing
24 ng DNA sperm nuclei. For the control reactions, the deple-
ted extract was replaced by 1.1 ml buffer LFB2/50 (40 mM
HEPES KOH, pH 8.0, 20 mM K2HPO4/KH2PO4, pH 8.0,
2 mM MgCl2, 1 mM EGTA, 2 mM DTT, 10% (w/v) sucrose,
and 1mg/ml each of leupeptin, pepstatinandaprotinin,0.1 mM
phenylmethlysulfonyl ﬂuoride, 2.5 mM ATP and 50 mM KCl)
containing the same quantity of sperm. Reactions were incu-
bated for 30 min at room temperature. An aliquot of 5.9 ml
extract supplemented with 60 nM geminin
DEL and
[a-
32P]dATP was added to the reactions and incubated for
a further 90 min. Total DNA synthesis was measured by
TCA precipitation.
Mcm(2,4,6,7) binding assay
The Mcm(2,4,6,7) complex was puriﬁed as described previ-
ously (28). A 20% slurry of glutathione Sepharose beads was
prepared in Hybrid buffer (2.5 mM ATP, 0.02% Triton,
4 mg/ml BSA, 100 mM KCl, 20 mM HEPES, 10% sucrose,
2 mM DTT, 10% imidazole, and 1 mg/ml leupeptin, aprotinin
and pepstatin). 50 ml aliquots were supplemented with 140 nM
GST-tagged Cdt1 constructs and 5 nM puriﬁed Mcm(2,4,
6,7). GST protein alone was used as a negative control. Rea-
ctions were incubated in 2 ml (square bottomed) Eppendorf
tubes on a rotating mixer at 6 r.p.m. for 30 min. The tubes were
spun down at 1000 g for 5 min, the supernatant was removed
and two rinses of 100 ml Hybrid buffer were carried out, with
spins between. An aliquot of 30 ml SDS loading buffer was
applied directly to the beads, boiled for 5 min and 20 ml
samples were loaded onto a gel and immunoblotted.
Overlay assay
Concentrations of constructs were standardized for the same
band intensity on an SDS gel stained with Coomassie. Those
concentrations were blotted to a nitrocellulose membrane.
After blocking in PBS + 0.02% Tween + 4% milk, the memb-
rane was then placed in a 50 ml Falcon tube containing 5 ml
LFB2/50 containing 15 nM geminin
DEL and 0.4% BSA. The
membrane was then blotted with rabbit anti-geminin antibody
and treated subsequently in a manner identical to a standard
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at a 37-fold lower concentration than the other proteins. This
dilution was used in order to normalize the signal intensity to
that of the other constructs.
Gel filtration and glycerol gradients
4 ml linear 10–30% glycerol gradients were formed in 20 mM
Tris–HCl, 1 mM EDTA, 200 mM NaCl, pH 7.5 using a
gradient mixer coupled to a peristaltic pump. Aliquots cont-
aining 200 ml samples of proteins of interest were applied to
the top of the gradient and centrifuged at 42000 g for 16 h in a
SW60 rotor (Beckman). Aliquots containing 200 ml fractions
were carefully collected from the top of the gradient using
a pipette.
Gel ﬁltration was performed essentially as described previ-
ously (16). Protein samples were applied to a 3.2 Superose 6
column equilibrated with TLFB1/200 (40 mM HEPES KOH,
pH 8, 20 mM K2HPO4/KH2PO4, pH 8.0, 2 mM MgCl2,1m M
EGTA, 2 mM DTT, 1 mg/ml aprotinin, pepstatin and leupeptin,
10% sucrose, 0.03% Triton and 200 mM KCl) at a ﬂow rate of
50 ml/min. Aliquots containing 30 fractions of 50 ml were
collected.
Molecular weight standards used were thyroglobulin
(669 kDa), ferritin (440 kDa), catalase (232 kDa), aldolase
(158 kDa), BSA (67 kDa), ovalbumin (43 kDa), chym-
otrypsinogen A (25 kDa) and ribonuclease A (13 kDa).
RESULTS
In order to investigate the structure and function of Xenopus
Cdt1, a range of GST-tagged constructs were designed. The
construct design was based on two regions predicted to form
coiled-coils (probabilities of 0.92 and 0.31 using MacStripe
v2.0) at residues 193–243 and 447–479, respectively. Out of a
total of 21 constructs, 17 generated informative results and are
described in this study (Figure 1).
Licensing activity of Cdt1 regions
The main activity that has been described for Cdt1 is as a
component of the pre-RC that loads Mcm2-7 onto DNA to
license it for subsequent replication (‘RLF-B’ activity)
(4,5,7,26,29). We ﬁrst determined the regions of Cdt1 that
are essential for this licensing activity. Sperm nuclei were
incubated in extract immunodepleted of endogenous Cdt1
supplemented with the different Cdt1 constructs; activity
was then assessed by either determining whether Mcm2 and
Mcm6 had been loaded onto chromatin (Figure 2A) or whether
thechromatincouldsubsequentlyreplicatewhentransferredto
extract containing an excess of active geminin (Figure 2B).
The results of both these assays were in agreement: the
N-terminal 243 amino acids were dispensable for licensing
activity, but residues between 243 and 311 were essential;
residues close to the C-terminus were required for licensing
activity, since deletion of the C-terminal 47 amino acids aboli-
shed activity. Residues 243–620 therefore represented the
smallest construct possessing licensing activity.
Previous work has suggested that licensing involves the
recruitment of Mcm2-7 to chromatin by direct interaction
with Cdt1 (11,12). Yanagi et al. (11) showed that mouse
Cdt1 possessed a binding site for Mcm6 in its C-terminus.
We therefore prepared a puriﬁed complex consisting of
Mcm2, 4, 6 and 7 (28) and used this to perform pull-down
experiments with different Xenopus Cdt1 constructs. The puri-
ﬁed Mcm(2,4,6,7) complex is shown in Figure 3A. Figure 3B
showsthatlikemouseCdt1,full-length XenopusCdt1canbind
to Mcm(2,4,6,7). The binding activity resides in the extreme
C-terminal 173 amino acids of Xenopus Cdt1, a region that is
necessary, but not sufﬁcient, for the licensing activity of Cdt1
(Figure 2). This is consistent with the idea that to function in
licensing, Cdt1 needs bind Mcm2-7, but also needs other
functions such as binding to ORC.
Geminin-binding activity of Cdt1 regions
The activity of Cdt1 is negatively regulated by binding
geminin (7,14,15), so we next set out to identify the regions
Figure 2. Licensing assay. (A) Interphase Xenopus egg extract or Cdt1-
depleted extract was supplemented with Xenopus sperm nuclei (10 ng DNA/
ml) and different GST-Cdt1 constructs at 5 nM. After incubation for 30 min,
chromatin was isolated and immunoblotted for the presence of Mcm2 and
Mcm6. (B) Cdt1-depleted extract was supplemented with Xenopus sperm
nuclei (11.5 ng DNA/ml) and different GST-Cdt1 constructs at 42 nM
(diagonal shading). After incubation for 30 min, aliquots were
supplemented with 2.8 vol of Xenopus egg extract supplemented with
[a-
32P]dATP and 60 nM geminin. After 90 min, total DNA synthesis was
assessed by TCA precipitation. As controls for the sufficiency of geminin
inhibition, assays were also performed, where the Cdt1-depleted extract was
replacedwithbuffer(whiteboxes).Theright-handpanelalsoshowstheactivity
of two His-tagged Cdt1 constructs (243–620 and 193–447).
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to deﬁne the interacting regions by pull-down assay were
inconclusive, probably due to the hydrophobicity of Cdt1
that tends to encourage non-speciﬁc interactions (7). To overc-
ome some of these problems, we performed an overlay (far-
western) assay. The Cdt1 constructs (Figure 4A) were blotted
onto nitrocellulose and then incubated with recombinant
geminin. The binding of geminin to the constructs was rev-
ealed using anti-geminin antibodies (Figure 4B). This assay
showed that at leasttwo different regions of Cdt1 were capable
of interacting with geminin. The ﬁrst region lies between the
two predicted coiled-coil domains; binding additionally req-
uired part of either of the two predicted coiled-coil domains.
The second region, somewhat surprisingly, comprises the
N-terminal 243 amino acids. The ﬁrst lane in the right-hand
panel of Figure 4A and B shows that in order to give a comp-
arable signal in the overlay assay, full-length Cdt1(1–620) had
to be used at a 37-fold lower concentration than the shorter
fragments containing one or other of the geminin-binding
domains. This suggests that both domains cooperate to bind
geminin. A recent paper has also implicated an additional
N-terminal domain in geminin binding (30).
We next investigated in more detail the binding of geminin
to Cdt1(193–447), which represents one of the shortest regions
of Cdt1 capable of binding geminin in the overlay assay. For
these experiments, we used a shortened version of geminin
(‘mini-geminin’), which is able to bind Cdt1 and inhibit
licensing in Xenopus egg extracts (13). His-tagged Cdt1
(193–447) and mini-geminin were expressed together or
separately in E.coli. After cell lysis, proteins were separated
into soluble and insoluble fractions. Figure 4C shows that
mini-geminin is found in the soluble fraction of E.coli lysates.
When applied to a nickel column, it was found exclusively in
the ﬂow-throughsinceit doesnotcontainaHistag. Incontrast,
Figure 3. Mcm2-7 binding assay. (A) Coomassie-stained gel of purified
Mcm2-7 used in the binding assay. The migration of molecular weight
markers is shown to the right (size in kDa). (B) Glutathione–Sepharose beads
were incubatedfor 30 min with 5 nM purified Mcm(2,4,6,7) and 140 nM GST-
tagged Cdt1 constructs. After washing, bead-bound protein was eluted and
immunoblotted for the presence of Mcm6.
Figure 4. Overlay (far-western) assay. (A and B) Different GST-Cdt1
constructs were separated by SDS–PAGE. (A) Gels were stained with
Coomassie. Molecular weight markers (sizes in kDa) are shown to the left.
(B)Proteinswereblottedontonitrocellulose.Afterblocking,the nitrocellulose
was incubated with recombinant geminin
DEL, followed by anti-geminin anti-
body and then anti-rabbit secondary antibody coupled to horseradish perox-
idase. Bound geminin was revealed by ECL chemiluminescence. To give a
comparable signal, Cdt1(1–620) was used at 37-fold lower concentration than
the other fragments and was not visible by Coomassie staining; the position of
theproteinisindicatedbyadashedoval.(C)His-taggedCdt1(193–447)andan
S-tagged version of geminin capable of binding Cdt1 (mini-geminin) were
expressedtogetherandseparatelyinE.coli.Afterproteinexpression,cellswere
lysedandtheproteinsseparatedintosolubleandinsolublecomponents.Soluble
protein was applied to nickel-NTA columns; the flow-through was collected,
and thenboundproteinwas elutedwithimidazole.Fractionswereseparatedby
SDS–PAGE and immunoblotted for Cdt1 and geminin.
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ioned almost exclusively into the insoluble fraction. Only
when co-expressed with mini-geminin was it found in the
soluble fraction. Furthermore, when co-expressed with His-
Cdt1(193–447), mini-geminin bound to a nickel column, des-
pite notpossessingaHistag ofitsown.These results show that
Cdt1(193–447) and mini-geminin can form a stable complex.
Both proteins ran as doublets on SDS–PAGE; western blot
analysis of the bands for mini-geminin showed that the lower
band had lost the S-tag, while the upper band still contained
the S-tag (data not shown). Mass spectrometry of the
Cdt1(193–447) doublet revealed that the lower band had
lost 10 amino acids from its C-terminus (data not shown).
In order to identify which of the regions of Cdt1 capable of
binding geminin in the overlay assay are physiologically imp-
ortant in binding geminin, we devised a competition assay.
Xenopus egg extract was supplemented with sufﬁcient rec-
ombinant geminin to completely abolish DNA replication;
recombinant Cdt1 constructs were then added to the geminin-
containing extract to compete with the endogenous Cdt1 for
geminin binding, and the extracts were then assayed for their
ability to support DNA replication. In principle, there are two
ways that the Cdt1 constructs could induce DNA replication in
this assay: they might provide licensing activity themselves, or
they may be able to compete with endogenous Cdt1 for
geminin binding, thereby liberating the endogenous Cdt1
and allowing it to induce DNA replication. Figure 5A
shows that, consistent with this idea, all the constructs that
possessed licensing activity (marked with an asterisk) were
able to support efﬁcient licensing in this assay. The N-terminal
243 amino acids, which lack licensing activity but bound
strongly to geminin in the overlay assay, were not able to
compete with the binding of endogenous full-length Cdt1.
In contrast, residues 193–447, consisting of the predicted
N-terminal coiled-coil plus the region between the predicted
coiled-coils, induced efﬁcient DNA synthesis although the
construct itself possessed no licensing activity. This suggests
that this region represents a domain that interacts strongly
enough with geminin to displace full-length endogenous
Cdt1 from its inhibitory interaction with geminin.
Taken together, the results shown so far suggest that the
predicted N-terminal coiled-coil domain of Xenopus Cdt1
(residues 193–243) is required for tight binding to geminin,
but is not required for licensing activity. Therefore, constructs
lacking the predicted N-terminal coiled-coil domain but poss-
essing licensing activity (i.e. residues 243–620) might be at
least partially resistant to inhibition by geminin. To investigate
this, Xenopus egg extract was supplemented with either full-
length Cdt1 (residues 1–620), Cdt1(243–620) or the tight
gemininbinderCdt1(193–447), plus increasingconcentrations
of geminin; the extracts were then assayed for their ability to
support DNA synthesis. Figure 5B shows that although full-
length Cdt1 or Cdt1(193–447) could rescue DNA synthesis in
the presence of low concentrations of geminin, rescue was
abolished at higher geminin concentrations. In contrast,
Cdt1(243–620), which lacks the predicted N-terminal
coiled-coil but possesses licensing activity, could still rescue
replication even at concentrations of geminin 16-fold higher
than were required to inhibit the other Cdt1 constructs capable
of binding to geminin. This suggests that the licensing activity
of Cdt1(243–620), which lacks the predicted N-terminal
coiled-coil domain, is at least partially resistant to inhibition
by geminin.
Stoichiometry of the geminin–Cdt1 complex
We next set out to determine the stoichiometry of geminin and
Cdt1 when complexed together. Gel ﬁltration of recombinant
Figure 5. Geminin neutralization. (A) Xenopus egg extract was supplemented
with sperm nuclei(3ng DNA/ml), 60 nM geminin
DEL,[ a-
32P]dATPand 50 nM
GST-Cdt1 constructs. After incubation for 90 min, total DNA synthesis was
assessed by TCA precipitation. Asterisked columns show constructs shown to
possess licensing activity. (B) Xenopus egg extract was supplemented with
sperm nuclei (3 ng DNA/ml), [a-
32P]dATP, various concentrations of
geminin
DEL and either 6.5 nM His-Cdt1(1–620) (black circles), 7.1 nM His-
Cdt1(243–620)(blacksquares),7.7nMHis-Cdt1(193–447)(whitetriangles)or
buffer alone (white circles). After incubation for 90 min, total DNA synthesis
was assessed by TCA precipitation.
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of 300 kDa (Stokes’ radius 54 s), similar to the behaviour
of endogenous geminin in Xenopus extract (16,27) (data not
shown). Glycerol gradient sedimentation of geminin
DEL
showed it migrating with an apparent molecular weight of
25 kDa (sedimentation value 2.5 · 10
13 S). Combining
these values in the equation of Siegel and Monty (31) gives a
value of 56600 kDa for the native molecular weight
of geminin, suggesting that it exists as a highly elongated
dimer, which is consistent with a number of recent reports
(22,30,32,33). We next co-expressed various constructs of
His-tagged Cdt1 and geminin in E.coli in order to produce
soluble complexes containing both proteins. Almost all of the
complexes we produced were insoluble or unstable. We did,
however, manage to produce reasonable quantities of a comp-
lex between the tight geminin binder Cdt1(193–447) and mini-
geminin. On gel ﬁltration, the complex of both proteins eluted
at an apparent molecular weight of 100 kDa (Stokes’ radius
40 s; Figure 6A). A small amount of protein with a larger
size was also observed. When the peak fraction was immunop-
recipitated with anti-geminin antibodies, Cdt1(193–447) was
efﬁciently co-precipitated, conﬁrming that this represents a
complex between mini-geminin and Cdt1(193–447)
(Figure 6B). On glycerol gradient sedimentation, the complex
of both proteins migrated at an apparent molecular weight of
50 kDa (sedimentation value 3.6 · 10
13 S; Figure 6C),
again with a small amount of protein at a larger size. The
Siegel and Monty equation suggests that the major peak of
protein represents a slightly elongated complex with a
molecular weight of 60 kDa. Monomeric Cdt1(193–447)
has a predicted molecular weight of 30 kDa, while monomeric
mini-geminin has a predicted molecular weight of 11.5 kDa.
A complex consisting of one molecule of Cdt1(193–447) and
two molecules of mini-geminin would therefore have a comb-
ined molecular weight of 53 kDa, close to the derived value.
Control experiments showed that on its own, the Cdt1(193–
447) construct was a monomer (Stokes’ radius 35 s, sedi-
mentation value 2 · 10
13 S; data not shown). To further
support our interpretation of the make-up of the complex, we
examined the composition of the complex on SDS–PAGE gels
stained with Coomassie (Figure 6D). Therelative intensitiesof
the bands were measured, giving a value of 0.72 for the ratio
of mini-geminin: Cdt1(193–447). Since the ratio of their
molecular weights is 0.38, the molar ratio of the proteins in
the complex is 1.9 mini-geminin: 1 Cdt1(193–447). This is
consistent with the complex consisting of two molecules of
mini-geminin and one molecule of Cdt1(193–447).
DISCUSSION
In the work presented here, we have mapped a number of
functional domains on Xenopus Cdt1. Our conclusions are
summarized in Figure 7A. The main function of Cdt1 is to
load Mcm2-7 onto chromatin to license the DNA for replica-
tion in the subsequent S phase. We show here that the
C-terminal 377 residues (amino acids 243–620) are required
for licensing activity. Licensing probably involves the direct
interaction between Cdt1 and Mcm2-7 (11,12). We show here
that the C-terminal 173 residues (amino acids 447–620) are
required for Cdt1 to interact with an Mcm(2,4,6,7) complex.
This is consistent with data from mouse Cdt1, showing that the
C-terminal 222 residues (corresponding to Xenopus Cdt1 resi-
dues 398–620) are necessary for interaction with Mcm6 (11).
It has been proposed that geminin inhibits Cdt1 function by
hindering accessof Mcm2-7 to this binding site(22).Although
the Mcm binding domain is necessary for licensing activity,
we show here that other regions of Cdt1 further to the
N-terminus are also required. This is plausible, since in add-
ition to binding Mcm2-7, Cdt1 presumably also needs to bring
them to ORC and Cdc6 on the DNA. It has previously been
shown that Cdt1 is directly recruited to DNA by ORC, and we
Figure 6. Characterization of complexes between Cdt1(193–447) and mini-
geminin.RecombinantcomplexesbetweenHis-Cdt1(193–447)andHis-tagged
mini-geminin were prepared. (A and B) Complexes were subject to gel filtra-
tion. (A) Fractions were subjected to SDS–PAGE and immunoblotted for Cdt1
and geminin. The migration of molecular weight markers (sizes in kDa) is also
shown.(B)ThepeakfractionofgemininandCdt1fromthegelfiltrationcolumn
was immunoprecipitated with either anti-geminin antibodies or non-immune
antibodies; precipitates were then immunoblotted for Cdt1 and geminin. (C)
Complexes were subject to glycerol gradient sedimentation. Fractions were
subjected to SDS–PAGE and immunoblotted for Cdt1 and geminin. The
migration of molecular weight markers (sizes in kDa) is also shown. (D)
Different quantities of the complex were subjected to SDS–PAGE and stained
with Coomassie.
322 Nucleic Acids Research, 2005, Vol. 33, No. 1propose that amino acids 243–447 of Cdt1 are required for this
recruitment.
Cdt1 is mainly controlled by binding to geminin, which
inhibits Cdt1’s licensing activity (7,14). In metazoans,
down-regulation of Cdt1 by geminin is a major mechanism
preventing re-replication of DNA in a single cell cycle
(7,16,17,20,34). We show here, using an overlay assay, that
at least two regions of Xenopus Cdt1 can interact with
geminin: a region between the predicted coiled-coil domains,
and a region at the N-terminus of the protein. Full-length Cdt1
bound geminin much more avidly than either domain alone.
Work on human Cdt1 also provides evidence for two different
geminin-binding domains in these regions (11,30,35,36).
However, we show here that only the central region (amino
acids 193–447), which includes the predicted N-terminal
coiled-coil domain, is capable of displacing geminin from
endogenous Cdt1 in a functional licensing assay. The pred-
icted N-terminal coiled-coil domain, while essential for a high
afﬁnity interaction with geminin, is not required for licensing
activity. Consistent with these ideas, Cdt1(243–620), which is
the minimal construct possessing licensing activity, was at
least partially resistant to inhibition by geminin. This construct
therefore has potential use in exploring the in vivo conseq-
uence of uncontrolled Cdt1 activity.
While we were preparing this work for publication, several
papers describing the structure of Cdt1 and geminin were
published (22,30,33,37). One of these papers describes a
crystal structure of a fragment of mouse geminin in complex
with a central region of Cdt1 (22). The region of mouse Cdt1
co-crystallized with geminin contained amino acids 172–368,
which corresponds to Xenopus Cdt1 residues 232–426. The
structure is likened to that of an axe, where geminin forms the
shaft and the Cdt1 fragment forms the blade (Figure 7B). Two
other papers present a crystal structure of geminin on its own,
showing a long coiled-coil dimer (30,33). Consistent with the
crystal structures, we provide evidence from glycerol gradient
sedimentation and gel ﬁltration that geminin forms a highly
elongated homodimer, and that each dimer of geminin can
interact with one molecule of Cdt1. Another recent paper
provides evidence that two geminin dimers can complex
together to form a tetramer (37). Although we ﬁnd no evidence
of this tetrameric structure, it is possible that the dimers int-
eract only weakly, and so the interaction is substantially disr-
upted during gel ﬁltration and glycerol gradient sedimentation.
The geminin–Cdt1 co-crystal shows a loop and a short helix
at the end of the geminin fragment, as well as the N-terminal
portion of the coiled-coil, interacting with the Cdt1 fragment
(22). From the results we present here, the Xenopus region
corresponding tothe Cdt1 fragmentin the co-crystal would not
be expected to bind to geminin tightly enough to displace
endogenous Cdt1 in the geminin neutralizing assay. For this
physiological interaction to take place, the predicted N-
terminal coiled-coil domain of Cdt1 is additionally required.
This predicted coiled-coil domain of Cdt1 is perfectly posit-
ioned to form a triple coiled-coil interaction with the geminin
‘shaft’, which would be expected to signiﬁcantly strengthen
the interaction between the two proteins (Figure 7B). In supp-
ort of this idea, residues in geminin towards the middle of the
shaft enhance the binding with Cdt1 and are essential for
inhibiting DNA replication (13,22,30,32,33). Like Xenopus
Cdt1, both human and mouse Cdt1 have a region of predicted
coiled-coil just N-terminal to the ‘blade’ fragment of Cdt1
(amino acids 113–152 in human Cdt1 and amino acids
126–163 in mouse Cdt1), consistent with the idea that this
is a conserved feature of metazoan Cdt1.
Previous work has shown that when overexpressed, geminin
is capable of selectively killing cancer cells (38,39). It is
therefore of considerable interest to understand how geminin
inhibits Cdt1. In providing further details of the geminin–Cdt1
interaction, the current work will help the design of molecular
mimics that display geminin’s capacity for cancer-speciﬁc cell
killing.
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